A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

Inclusion Criteria: * Male and female participants ages 2-15 years * Documented detrusor overactivity associated with a known neurological condition such as meningomyelocele or spinal cord injury, and confirmed by urodynamics at baseline * Using clean intermittent catheterization (CIC) on a regular basis * Participating in a bowel program on a regular basis * Able to swallow the study medication in accordance to the protocol * Participants and/or parent/guardian able to complete the bladder diary and follow the study procedures Exclusion Criteria: * Treatment with drugs known to significantly affect the urinary bladder and urinary bladder outlet function * Fecal impaction. Participants may be included, once this condition has resolved * Clinically significant anatomical abnormalities or acquired disorders of the urinary tract * Previous reconstructive surgery (augmentation etc.) of the bladder or bladder outlet * Symptomatic urinary tract infection unresolved at time of urodynamic study and/or completion of bladder diary. * Diabetes insipidus * Electro stimulation therapy or bladder training within 2 weeks prior to Visit 1 and at any time during the study * Concomitant diseases, in which the use of darifenacin is contraindicated * History of hypersensitivity to darifenacin or to drugs with similar chemical structures * Participants with any physical and cognitive impairment or any other condition which in the opinion of the investigator makes the participants unsuitable fo…